查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1789868

Dupixent 市场规模、份额和趋势分析报告：按适应症、分销管道、地区和细分市场预测，2025 年至 2033 年

Dupixent Market Size, Share & Trends Analysis Report By Indication (Atopic Dermatitis, Asthma, Chronic Rhinosinusitis With Nasal Polyps, Chronic Obstructive Pulmonary Disease ), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

Dupixent 市场摘要

预计 2024 年全球 Dupixent 市场规模为 141.5 亿美元，预计 2033 年将达到 275.8 亿美元，2025 年至 2033 年的复合年增长率为 7.70%。 Dupixent 产业反映了从传统治疗方法转向生技药品的转变。

这一增长是由全球 2 型发炎性疾病盛行率的不断上升所驱动，包括异位性皮肤炎、气喘和伴随鼻息肉的慢性鼻窦炎，以及近期监管部门核准的水痘天疱疮和嗜伊红性食道炎新适应症。市场成长是由治疗 2 型发炎性疾病的需求所驱动。赛诺菲和再生元开发的 Dupixent 在临床试验中已证明其有效性和安全性，在治疗异位性皮肤炎和气喘等疾病方面优于皮质类固醇等传统选择。这一转变是由全球盛行率的不断上升所支持的，据报道，到 2024 年，将有超过 2 亿人患有异位性皮肤炎，超过 3 亿人患有气喘。

Dupixent 的市场扩张主要由研发驱动，并得到新治疗领域临床试验的支持。正在进行的试验，例如用于治疗慢性自发性荨麻疹的 LIBERTY-CSU CUPID 试验和用于治疗嗜伊红性食道炎和用于治疗水痘天疱疮的核准（预计于 2024 年 1 月）预计将提高患者合格，并增强其在 2033 年之前的长期产生收入。这些努力得到了真实世界证据的支持，正在巩固 Dupixent 在发炎性疾病和罕见免疫适应症领域的地位。

赛诺菲与再生元的全球合作有助于加速监管核准，并强化市场进入平台。美国药物管理局 (FDA) 于2025年6月核准Dupixent用于治疗慢性阻塞性肺病 (COPD) 和水痘天疱疮，这标誌着一项战略里程碑，将Dupixent的核准适应症扩展至九种，包括伴有鼻息肉的慢性鼻窦炎和结节性痒疹。这巩固了Dupixent在白细胞介素抑制剂领域的地位，而其在北美、欧洲和亚太地区的全球扩张正由协调一致的监管和商业策略推动。

在美国和日本等主要市场，专利保护期至2033年，降低了中期生物相似药带来的竞争风险。此外，製造流程的复杂性和专业化设施也阻碍力了新进入者的进入。市场扩张的机会仍然存在，尤其是在拉丁美洲、中东和非洲等尚未开发的地区。巴西和沙乌地阿拉伯等国家拥有庞大的患者群体，这得益于医疗改革和生技药品需求的不断增长。在地化的定价策略和分销伙伴关係预计将促进在地化药物的取得。

欧洲孤儿药专营权等监管激励措施，加上强大的开发平臺，支撑了持续成长。然而，2033年后的市场动态，包括欧洲和亚太地区的生物相似药准入和定价限制，凸显了製定适应性报销策略和患者可及性计划以保持盈利的必要性。

目录

第一章调查方法与范围

第二章执行摘要

3. Dupixent 市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章 Dupixent 市场：按适应症进行的业务分析

  • 2024 年及 2033 年各适应症市场占有率分析
  • 指示细分仪表板
  • 市场规模、预测与趋势分析（按适应症，2021-2033 年）
  • 异位性皮肤炎（AD）
  • 气喘
  • 慢性鼻窦炎伴随鼻息肉（CRSwNP）
  • 慢性阻塞性肺病（COPD）
  • 其他的

5. Dupixent 市场：按分销管道进行的业务分析

  • 2024 年及 2033 年通路市场占有率分析
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析（2021-2033 年）
  • 医院药房
  • 零售药局
  • 其他的

第六章：Dupixent 市场：区域估计与趋势分析

  • 2024 年及 2033 年区域市场占有率分析
  • 地理细分仪表板
  • 市场规模及预测趋势分析（按地区，2021-2033）
  • 北美洲
    • 按国家/地区，2021-2033 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Sanofi
    • Regeneron
Product Code: GVR-4-68040-657-9

Dupixent Market Summary

The global dupixent market size was estimated at USD 14.15 billion in 2024, and is projected to reach USD 27.58 billion by 2033, growing at a CAGR of 7.70% from 2025 to 2033. The Dupixent industry reflects a transition from traditional therapies to biologics.

Anchored by its innovative interleukin-4 and interleukin-13 inhibition mechanism, this growth is driven by the increasing global prevalence of Type 2 inflammatory diseases, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, along with recent regulatory approvals for new indications such as bullous pemphigoid and eosinophilic esophagitis. The market growth is driven by the need for treatments addressing Type 2 inflammatory diseases. Dupixent, developed by Sanofi and Regeneron, demonstrates efficacy and safety in clinical trials, surpassing conventional options like corticosteroids for conditions including atopic dermatitis and asthma. This shift is supported by increasing global prevalence, with over 200 million atopic dermatitis patients and 300 million asthma cases reported in 2024.

Research and development efforts are a key driver of the Dupixent market's expansion, supported by clinical trials across new therapeutic areas. Ongoing studies such as LIBERTY-CSU CUPID for chronic spontaneous urticaria and trials in allergic fungal rhinosinusitis aim to broaden the drug's reach to new patient populations. Pediatric trials for eosinophilic esophagitis and approved use in bullous pemphigoid (January 2024) are expected to enhance patient eligibility and strengthen long-term revenue generation through 2033. These initiatives, supported by real-world evidence, are increasing Dupixent's positioning across inflammatory and rare immunologic indications.

Sanofi and Regeneron's global collaboration facilitates accelerated regulatory approvals and strengthens market access infrastructure. U.S. FDA approvals in June 2025 for COPD and bullous pemphigoid mark strategic milestones, expanding Dupixent's approved indications to nine, including chronic rhinosinusitis with nasal polyps and prurigo nodularis. This has reinforced the drug's standing in the interleukin inhibitor class, with global rollout in North America, Europe, and Asia Pacific driven by a coordinated regulatory and commercialization strategy.

Patent protection in major markets such as the U.S. and Japan until 2033 reduces biosimilar competition risk in the medium term. Additionally, manufacturing complexity and specialized facilities act as deterrents for new entrants. Market expansion opportunities remain in underpenetrated regions, particularly Latin America and the Middle East & Africa. Countries such as Brazil and Saudi Arabia present significant patient pools, supported by healthcare reforms and increasing biologics demand. Localized pricing strategies and distribution partnerships are expected to drive regional access.

Regulatory incentives such as orphan drug exclusivity in Europe, combined with a strong development pipeline, support sustained growth. However, post-2033 market dynamics, including biosimilar entry and pricing constraints in Europe and Asia Pacific, highlight the need for adaptive reimbursement strategies and patient access programs to maintain profitability.

Global Dupixent Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Dupixent market report based on indication, distribution channel, and region:

  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Atopic Dermatitis (AD)
  • Asthma
  • Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Dupixent Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Dupixent Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2033
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 4.4. Atopic Dermatitis (AD)
    • 4.4.1. Atopic Dermatitis (AD) Market, 2021 - 2033 (USD Million)
  • 4.5. Asthma
    • 4.5.1. Asthma Market, 2021 - 2033 (USD Million)
  • 4.6. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
    • 4.6.1. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, 2021 - 2033 (USD Million)
  • 4.7. Chronic Obstructive Pulmonary Disease (COPD)
    • 4.7.1. Chronic Obstructive Pulmonary Disease (COPD) Market, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Dupixent Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Dupixent Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Dupixent Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Sanofi
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Regeneron
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Dupixent market, by region, 2021 - 2033 (USD Million)
  • Table 4. Global Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 5. Global Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6. North America Dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 7. North America Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 8. North America Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9. U.S. Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 10. U.S. Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11. Canada Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 12. Canada Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13. Mexico Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 14. Mexico Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15. Europe Dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 16. Europe Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 17. Europe Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 18. UK Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 19. UK Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20. Germany Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 21. Germany Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22. France Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 23. France Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24. Italy Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 25. Italy Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 26. Spain Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 27. Spain Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28. Norway Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 29. Norway Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30. Denmark Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 31. Denmark Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32. Sweden Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 33. Sweden Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34. Asia Pacific Dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 35. Asia Pacific Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 36. Asia Pacific Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 37. Japan Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 38. Japan Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39. China Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 40. China Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41. India Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 42. India Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43. Australia Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 44. Australia Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45. South Korea Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 46. South Korea Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47. Thailand Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 48. Thailand Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 49. Latin America Dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 50. Latin America Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 51. Latin America Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52. Brazil Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 53. Brazil Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54. Argentina Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 55. Argentina Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56. Middle East & Africa Dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 57. Middle East & Africa Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 58. Middle East & Africa Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59. South Africa Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 60. South Africa Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61. Saudi Arabia Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 62. Saudi Arabia Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 63. UAE Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 64. UAE Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65. Kuwait Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 66. Kuwait Dupixent market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Dupixent market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Dupixent market dynamics
  • Fig. 12 Dupixent market: Porter's five forces analysis
  • Fig. 13 Dupixent market: PESTLE analysis
  • Fig. 14 Product market, 2021 - 2033 (USD Million)
  • Fig. 15 Atopic Dermatitis (AD) market, 2021 - 2033 (USD Million)
  • Fig. 16 Asthma market, 2021 - 2033 (USD Million)
  • Fig. 17 Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) market, 2021 - 2033 (USD Million)
  • Fig. 18 Chronic Obstructive Pulmonary Disease (COPD) market, 2021 - 2033 (USD Million)
  • Fig. 19 Others market, 2021 - 2033 (USD Million)
  • Fig. 20 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 21 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 22 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 23 Others market, 2021 - 2033 (USD Million)
  • Fig. 24 Dupixent market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 North America Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. country dynamics
  • Fig. 28 U.S. Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 29 Canada country dynamics
  • Fig. 30 Canada Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 31 Mexico country dynamics
  • Fig. 32 Mexico Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 33 Europe Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 34 UK country dynamics
  • Fig. 35 UK Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 36 Germany country dynamics
  • Fig. 37 Germany Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 38 France country dynamics
  • Fig. 39 France Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 40 Italy country dynamics
  • Fig. 41 Italy Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 42 Spain country dynamics
  • Fig. 43 Spain Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 44 Norway country dynamics
  • Fig. 45 Norway Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 46 Sweden country dynamics
  • Fig. 47 Sweden Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 48 Denmark country dynamics
  • Fig. 49 Denmark Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 50 Asia Pacific Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 51 Japan country dynamics
  • Fig. 52 Japan Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 55 India country dynamics
  • Fig. 56 India Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 57 Australia country dynamics
  • Fig. 58 Australia Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 61 Thailand country dynamics
  • Fig. 62 Thailand Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 63 Latin America Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 64 Brazil country dynamics
  • Fig. 65 Brazil Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 66 Argentina country dynamics
  • Fig. 67 Argentina Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 68 MEA Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 69 South Africa country dynamics
  • Fig. 70 South Africa Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 71 Saudi Arabia country dynamics
  • Fig. 72 Saudi Arabia Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 73 UAE country dynamics
  • Fig. 74 UAE Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 75 Kuwait country dynamics
  • Fig. 76 Kuwait Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 77 Company categorization
  • Fig. 78 Company market position analysis
  • Fig. 79 Strategic framework